Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss

Basel, 17 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today results from two phase III studies evaluating the efficacy and safety of two doses of investigational vamikibart (0.25 and 1 mg) compared with a sham procedure that mimics intravitreal (IVT) injections in people with uveitic macular edema (UME).¹ UME is characterised by the buildup of fluid in the macula due to uveitis, an inflammatory condition of the eye, that can result in vision loss.² Across both studies, the primary and secondary endpoint data support the potential for rapid improvements in vision and reductions in macular thickness  (swelling in the back of the eye due to retinal fluid) with vamikibart treatment.¹ The data were presented at the American Academy of Ophthalmology annual meeting (AAO 2025) in Orlando, Florida, United States.